NVAX Earnings Prediction
The chart below shows how NVAX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, NVAX sees a -2.45% change in stock price 10 days leading up to the earnings, and a +0.19% change 10 days following the report. On the earnings day itself, the stock moves by +9.95%. This data can give you a slight idea of what to expect for the next quarter's release.
NVAX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
84.51M
-54.80%
-79.66%
Gross Margin
28.27%
-39.97%
-68.23%
Operating Margin
-153.61%
127.91%
-493.77%
Net Margin
-143.53%
105.22%
-467.27%
EPS
-0.76
-39.68%
-176.77%
No Data Available
NVAX Earnings Analysis
Novavax Inc Corporation (NVAX.O) Earnings Conference Call
Positive
Q3 Revenue Surge: Total revenue for Q3 2024 was $85 million, a significant increase from $18.7 million in the same period in 2023, primarily driven by U.S. market sales.
Q3 Product Sales Surge: Product sales for Q3 2024 reached $38 million, compared to $2 million in the same period for 2023, reflecting higher U.S. market sales in the current quarter.
Expense Reduction Achievement: Combined R&D and SG&A expenses for Q3 2024 were $158 million, representing a 26% reduction from the same period in 2023.
Strong Cash Position: The company ended Q3 2024 with over $1 billion in cash and cash equivalents, maintaining a strong cash position.
Cost Reduction Initiative: NovaVax is prepared to initiate an additional cost reduction program to better align its cost structure with its value creation strategy.
Negative
Revenue Decline Q3 2024: Total revenue for Q3 2024 was $85 million, down from $187 million in the same period in 2023.
Sales Performance Decline: Product sales for Q3 2024 were $38 million compared to $2 million in the same period for 2023, indicating a significant drop in overall sales performance.
Cost Reduction Strategies: Combined R&D and SG&A expenses for Q3 2024 were $158 million, reflecting a 26% reduction from the same period in 2023, indicating cost-cutting measures.
Market Share Underperformance: The current market share of approximately 3% is trending below full season expectations, suggesting underperformance in market penetration.
Revenue Guidance Revision: The revised guidance for total revenue for the fully year 2024 is now between $650 million and $700 million, down from previous expectations of $700 million to $800 million.
NVAX FAQs
How does NVAX typically perform around its earnings report dates?
Is Novavax, Inc. (NVAX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
NVAX Earning Call Sentiment
Novavax, Inc. (NVAX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
NVAX.O
1.03%Positive
The earnings call reveals several concerning factors: a decrease in revenue guidance, supply chain challenges, and vague responses in the Q&A, particularly regarding trial timelines and safety concerns. Despite a strong partnership with Sanofi, the overall financial performance and market conditions appear weak. The market cap suggests a moderate reaction, resulting in a predicted negative stock movement of -2% to -8% over the next two weeks.